<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714595</url>
  </required_header>
  <id_info>
    <org_study_id>1424R2131</org_study_id>
    <secondary_id>2015-004703-23</secondary_id>
    <nct_id>NCT02714595</nct_id>
  </id_info>
  <brief_title>Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens</brief_title>
  <acronym>CREDIBLE - CR</acronym>
  <official_title>A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide evidence of efficacy of S-649266 in the treatment of
      serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to provide evidence of efficacy of S-649266 in the treatment of
      serious infections in adult patients with either hospital-acquired pneumonia
      (HAP)/ventilator-associated pneumonia (VAP)/healthcare-associated pneumonia (HCAP),
      complicated urinary tract infection (cUTI), or bloodstream infections (BSI)/sepsis caused by
      carbapenem-resistant Gram-negative pathogens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome per patient at test of cure (TOC) in patients with HAP/VAP/HCAP or BSI/sepsis</measure>
    <time_frame>Test of cure, defined as 7 days after end of treatment (treatment duration is 7-14 days)</time_frame>
    <description>For HAP/VAP/HCAP, clinical cure is defined as resolution or substantial improvement of baseline signs and symptoms of pneumonia including a reduction in SOFA and CPIS scores, and improvement or lack of progression of chest radiographic abnormalities such that no antibacterial therapy is required for the treatment of the current infection. For BSI/sepsis clinical cure is the resolution or substantial improvement of baseline signs and symptoms including a reduction in SOFA score, such that no antibacterial therapy is required for the treatment of BSI/sepsis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiologic outcome (for Gram-negative pathogen) per patient at TOC in patients with cUTI</measure>
    <time_frame>7 days after end of treatment (7-14 days)</time_frame>
    <description>Eradication is defined as a urine culture showing that the baseline Gram-negative uropathogen found at entry at â‰¥ 10^5 colony forming units (CFU)/mL are reduced to &lt; 10^4 CFU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome per patient at end of treatment (EOT) (HAP/VAP/HCAP or BSI/sepsis)</measure>
    <time_frame>End of treatment (7-14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome per pathogen at EOT and TOC (HAP/VAP/HCAP or BSI/sepsis)</measure>
    <time_frame>End of treatment (7-14 days), and 7 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome per patient/pathogen at EOT and TOC (cUTI)</measure>
    <time_frame>End of treatment (7-14 days) and 7 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic outcome (for Gram-negative pathogen) per patient/pathogen at EOT, TOC, and follow-up (FUP) (HAP/VAP/HCAP or BSI/sepsis)</measure>
    <time_frame>End of treatment, 7 days after end of treatment and 14 days after end of treatment (follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic outcome (for Gram-negative pathogen) per patient at EOT, and FUP (cUTI)</measure>
    <time_frame>End of treatment (7-14 days) and 14 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic outcome (for Gram-negative pathogen) per pathogen at EOT, TOC, and FUP (cUTI)</measure>
    <time_frame>End of treatment (7-14 days) and at 7 days and 14 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic outcome with documented carbapenem-resistant Gram-negative bacteremia (regardless of primary infection diagnosis) at EOT, TOC, and FUP</measure>
    <time_frame>End of treatment (7-14 days) and at 7 days and 14 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with positive clinical and microbiologic outcome at EOT and TOC (cUTI only)</measure>
    <time_frame>End of treatment (7-14 days) and 7 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at Day 14 and Day 28 for HAP/VAP/HCAP and BSI/sepsis</measure>
    <time_frame>Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of survival and no change in antibiotic treatment due to either lack of therapeutic benefit or drug-related toxicity at TOC</measure>
    <time_frame>7 days after end of treatment (7-14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time (HAP/VAP/HCAP, BSI/sepsis)</measure>
    <time_frame>Up to 28 days after the end of treatment (7-14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infection Score (CPIS) at EOT and TOC (HAP/VAP/HCAP only)</measure>
    <time_frame>End of treatment (7-14 days) and 7 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score at EOT and TOC</measure>
    <time_frame>End of treatment and 7 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From Baseline to 28 days after end of treatment (7-14 days)</time_frame>
    <description>Safety and tolerability profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthcare-associated Pneumonia (HCAP)</condition>
  <condition>Bloodstream Infections (BSI)</condition>
  <condition>Hospital Acquired Pneumonia (HAP)</condition>
  <condition>Complicated Urinary Tract Infection (cUTI)</condition>
  <condition>Sepsis</condition>
  <condition>Ventilator Associated Pneumonia (VAP)</condition>
  <arm_group>
    <arm_group_label>S-649266</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive S-649266 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Available Therapy (BAT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BAT will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-649266</intervention_name>
    <description>2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function).</description>
    <arm_group_label>S-649266</arm_group_label>
    <other_name>cefiderocol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Available Therapy</intervention_name>
    <description>Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).</description>
    <arm_group_label>Best Available Therapy (BAT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinically documented infection (HAP/VAP/HCAP, cUTI, or BSI/sepsis)
             caused by a Gram-negative pathogen with evidence of carbapenem resistance

          -  Patients who have been treated previously with an empiric antibiotic regiment and
             failed treatment, both clinically and microbiologically, are eligible for the study,
             if they have an identified carbapenem-resistant Gram-negative pathogen which has
             either been shown to be nonsusceptible in vitro to each of the antibiotic(s) of the
             empiric antibiotic regimen or been grown from a culture performed after at least two
             days of the empiric antibiotic regimen

          -  Patient is male (no contraception required) or female and meets one of the following
             criteria:

               -  Surgically sterile by hysterectomy and/or bilateral oophorectomy or bilateral
                  salpingectomy or tubal ligation for the purpose of contraception for at least 6
                  weeks with appropriate documentation of such surgery

               -  Postmenopausal (defined as older than 45 years of age with cessation of regular
                  menstrual periods for 6 months and confirmed by a follicle-stimulating hormone
                  level of &gt; 40 mIU/ml, or amenorrhea for at least 12 months)

               -  Of childbearing potential and using combined (estrogen and progestogen) or
                  progestogen-only hormonal contraception associated with inhibition of ovulation
                  (including oral, intravaginal, injectable, implantable, and transdermal
                  contraceptives), or an intrauterine device (IUD), or intrauterine
                  hormone-releasing system (IUS) for the entire duration of the study

               -  Of childbearing potential and practice abstinence as a preferred and usual
                  lifestyle, and agrees to continue practicing abstinence from screening up to 14
                  days after the last dose of study drug

               -  Of childbearing potential, whose sole heterosexual partner has been successfully
                  vasectomized and agrees to not have other heterosexual partners for the entire
                  duration of the study

          -  Patients meeting specific criteria for each infection site

        Exclusion Criteria:

          1. Patients who have a documented history of any moderate or severe hypersensitivity or
             allergic reaction to any Î²-lactam (Note: for Î²-lactams, a history of a mild rash
             followed by uneventful re-exposure is not a contraindication to enrollment)

          2. Patients who need more than 3 systemic antibiotics as part of best available therapy
             (BAT) for the treatment of the Gram-negative infection (patients with mixed
             Gram-positive or anaerobic infections may receive appropriate concomitant narrow
             spectrum antibiotics [eg, vancomycin, linezolid, metronidazole, clindamycin])

          3. Patients with coinfection caused by invasive aspergillosis, mucormycosis or other
             highly lethal mold

          4. Patients who have central nervous system (CNS) infection (eg, meningitis, brain
             abscess, shunt infection)

          5. Patients with infection requiring &gt; 3 weeks of antibiotic treatment (eg, bone and
             joint infection, endocarditis)

          6. Patients with cystic fibrosis or bronchiectasis

          7. Patients in refractory septic shock defined as persistent hypotension despite
             adequate fluid resuscitation or despite vasopressive therapy at the time of
             Randomization

          8. Patients with severe neutropenia, ie, polymorphonuclear neutrophils (PMNs) &lt; 100
             cells/Î¼L

          9. Female patients who have a positive pregnancy test at Screening or who are lactating

         10. Patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) score &gt;
             30

         11. Patients who have received a potentially effective antibiotic regimen for the
             carbapenem-resistant Gram-negative infection for a continuous duration of more than
             24 hours in cUTI, or 36 hours in HAP/VAP/HCAP or BSI/sepsis during the 72 hours
             leading to Randomization

         12. Patients with any condition or circumstance that, in the opinion of the investigator,
             would compromise the safety of the patient or the quality of the study data

         13. Patients requiring continuing treatment with methotrexate, procainamide, or
             probenecid

         14. Patients who have received another investigational drug or device within 30 days
             prior to study entry

         15. Patients who have previously been randomized in this study or received S-649266

         16. Patients receiving peritoneal dialysis

         17. Patients meeting specific exclusion criteria for each infection site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <phone>800-849-9707</phone>
    <email>Shionogiclintrials-admin@shionogi.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30140-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Campinas</city>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Caxias do Sul</city>
        <zip>95070-561</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>8530-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Passo Fundo</city>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90160-093</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Salvador</city>
        <zip>40140-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Santa Maria</city>
        <zip>97 105-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>SÃ£o JosÃ© do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>04378-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Cholargos</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Larisa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Larisa</city>
        <zip>41221</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Ciudad de Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Be'er Sheba</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Be'er Ya'akov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Aichi</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8999</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Hualien</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>ROC</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Tainan City</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Tainan City</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Muang Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Muang</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Bornova/Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Ä°stanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>London</city>
        <zip>W 120NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>February 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cefiderocol</keyword>
  <keyword>Bloodstream infections (BSI)</keyword>
  <keyword>Complicated urinary tract infection (cUTI)</keyword>
  <keyword>Ventilator associated pneumonia (VAP)</keyword>
  <keyword>Hospital acquired pneumonia (HAP)</keyword>
  <keyword>Sepsis</keyword>
  <keyword>multi-drug resistant pathogens</keyword>
  <keyword>S-649266</keyword>
  <keyword>Gram-negative pathogens</keyword>
  <keyword>Healthcare-associated pneumonia (HCAP)</keyword>
  <keyword>carbapenem resistant pathogens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
